Hubble - brand of contact lenses sold directly to consumers through an e-commerce, subscription-only model.
Kronos Bio - research and development of therapies that modulate historically recalcitrant cancer targets.
Neogene Therapeutics - biomedical company developing T cell therapies that target mutated proteins in cancer.
UroGen Pharma - clinical-stage biopharmaceutical company developing therapies with a focus on uro-oncology.
Past holdings:
Arno Therapeutics - clinical-stage biopharmaceutical company that is developing products for the treatment of cancer.
Capricor Therapeutics - private biotherapeutics company pioneering breakthrough science to develop disruptive cell-based therapies for cancer and other devastating diseases. Cell Design Labs leverages the power of the body’s immune system to develop smart, living therapies with the capability to treat our most challenging diseases with unprecedented power, precision, safety and durability.
Edgemont Pharmaceuticals - privately held pharmaceutical company in the field of neuroscience.
Kite Pharma - clinical-stage biopharmaceutical company focused on developing engineered autologous cell therapy products for the treatment of cancer.
Sienna Biopharmaceuticals - discovery, clinical development and commercialization of products in dermatology and aesthetics
Velcera - develops pet medicines in pain management, anti-allergy and parasiticides
Veterinary Prime - pet nutrition products for dogs and cats, sold through veterinarians.
In October 2013, Arno Therapeutics completed a $30.7 million financing of equity.
In November 2013, Nile Therapeutics completed a merger with Capricor to form Capricor Therapeutics. Capricor has become a wholly owned subsidiary of Nile.
In April 2014, Kite Pharma completed a $50 million mezzanineprivate financing of convertible notes, and in May, the company filed a registration with the SEC for an IPO of its common stock, with a proposed maximum offering price of $115 million. The company listed on the NASDAQ Global Market under the symbol “KITE.” The company planned to raise $78 million by offering 6 million shares at a price range of $12.00 to $14.00. At the midpoint of the proposed range, Kite Pharma would command a market value of $548 million. On 20 June 2014, 7.5 million shares of Kite Pharma, priced at $17 a share began trading on the NASDAQ, indicating a market valuation of $632.4 million for the company.
In March 2017, it was reported that Two River has participated in a $16.5 million Series A round of funding for Hubble.
